Nautilus Biotechnology posts first revenue, Q2 net loss narrows

Overview

• US proteomics platform developer reported first revenue in Q2 2026, driven by grant and service sales

• Operating expenses fell 7% yr/yr, net loss narrowed slightly from prior year

• Company shifted resources to accelerate proteoform applications, with no incremental spend

Outlook

• Nautilus expects Voyager platform pre-orders in early 2027, instrument shipments in mid 2027

• Company anticipates general availability of Tau and AKT1 consumable kits in mid 2027

• Nautilus plans to report commercial timeline for Broadscale Assay at a future date

Result Drivers

• FIRST REVENUE SOURCES - Q2 revenue driven by grant from Michael J. Fox Foundation and initial service sales under Iterative Mapping Early Access Program

• RESOURCE REALLOCATION - Co shifted resources to accelerate proteoform applications in response to customer demand, without increasing overall spending

• LOWER OPERATING COSTS - Operating expenses fell due to lower salaries, stock-based compensation, and facilities costs

Company press release: ID:nGNX23sBnH

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology medical research peer group is "buy."

• Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $4.00, about 141% above its July 27 closing price of $1.66

Reuters Recommended Reads

• July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook

• July 28 - Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales

• July 27 - UK's Science Group preliminary H1 core revenue falls; expects buyback to exceed £20 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)